BG Medicine (OTCMKTS:BGMD) and Ardent Health (NYSE:ARDT) Head to Head Comparison

BG Medicine (OTCMKTS:BGMD) and Ardent Health (NYSE:ARDT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Valuation & Earnings

This table compares BG Medicine and Ardent Health”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BG Medicine	N/A	N/A	N/A	N/A	N/A
Ardent Health	$5.97 billion	0.21	$210.34 million	$1.45	6.15

Ardent Health has higher revenue and earnings than BG Medicine.

Volatility & Risk

BG Medicine has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Comparatively, Ardent Health has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BG Medicine and Ardent Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BG Medicine	0	0	0	0	0.00
Ardent Health	2	4	6	0	2.33

Ardent Health has a consensus target price of $14.67, suggesting a potential upside of 64.42%. Given Ardent Health’s stronger consensus rating and higher probable upside, analysts clearly believe Ardent Health is more favorable than BG Medicine.

Profitability

This table compares BG Medicine and Ardent Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BG Medicine	N/A	N/A	N/A
Ardent Health	3.24%	19.02%	6.04%

Summary

Ardent Health beats BG Medicine on 7 of the 8 factors compared between the two stocks.

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

About Ardent Health

Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.